Pathologic Assessment of Lymph Node Involvement in Patients Undergoing Mastectomy

Mehrasa, Parisa; Nasseri, Ali Reza; Seyed Hoseini, Seyed Vahid

doi:10.5281/zenodo.21924014

Pathologic Assessment of Lymph Node Involvement in Patients Undergoing Mastectomy

Document Type : Original Article

Authors

Parisa Mehrasa ¹

Ali Reza Nasseri ²

Seyed Vahid Seyed Hoseini ³

¹ Assistant Professor of Pathology, Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

² Assistant Professor of Radiotherapy, Department of Radiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

³ Assistant Professor of Surgery, Department of General Surgery, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

https://doi.org/10.5281/zenodo.21924014

Abstract

Introduction: Breast cancer remains a major global health burden, and lymph node involvement is a key pathologic indicator of tumor spread, prognosis, and postoperative treatment planning in patients undergoing mastectomy. Accurate nodal assessment also improves disease staging and therapeutic decision-making. This study aims to evaluate the pathologic status of lymph node involvement in patients undergoing mastectomy.

Material and methods: This retrospective descriptive cross-sectional study was conducted at Shahid Madani Hospital in Tabriz on 250 patients selected by convenience sampling, with sample size estimated using Cochran’s formula. Data were extracted from archived medical and pathology records, and clinicopathologic variables, particularly lymph node status and related breast tumor characteristics, were systematically collected and analyzed to evaluate the pattern of nodal involvement in mastectomy patients.

Results: Among 250 mastectomy patients, invasive ductal carcinoma was the predominant subtype (79.2%), most tumors were grade II (57.2%), and mean tumor size was 3.41 ± 1.67 cm. Lymph node involvement was present in 58.4%, with macrometastasis in 51.2% and extranodal extension in 15.6%. Nodal positivity was significantly associated with larger tumor size (3.98 ± 1.78 vs. 2.61 ± 1.14 cm, P < 0.001), higher grade (P = 0.002), and lymphovascular invasion (60.3% vs. 23.1%, P < 0.001).

Conclusion: These findings indicate that lymph node metastasis is common in mastectomy specimens and is closely linked to adverse pathologic features. Larger tumors, higher histologic grade, and lymphovascular invasion appear to be the strongest correlates of nodal spread, underscoring the importance of careful pathologic lymph node assessment for accurate staging, prognostic stratification, and postoperative treatment planning in breast cancer patients.

Graphical Abstract

Pathologic Assessment of Lymph Node Involvement in Patients Undergoing Mastectomy

Keywords

Breast cancer

Lymph node involvement

Mastectomy

Pathologic evaluation

Subjects

Cancer

[1] Boileau, J.-F., Poirier, B., Basik, M., et al. (2015). Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study. Journal of Clinical Oncology, 33(3), 258–264.

[2] Botty Van den Bruele, A., Lavery, J., Plitas, G., & Pilewskie, M. L. (2021). Axillary downstaging in occult primary breast cancer after neoadjuvant chemotherapy. Annals of Surgical Oncology, 28(2), 968–974.

[3] Boughey, J. C., Ballman, K. V., Le-Petross, H. T., et al. (2016). Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy: Results from ACOSOG Z1071 (Alliance). Annals of Surgery, 263(4), 802–807.

[4] Boughey, J. C., Suman, V. J., Mittendorf, E. A., et al. (2013). Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial. JAMA, 310(14), 1455–1461.

[5] Brown, L. D., Cai, T. T., & DasGupta, A. (2001). Interval estimation for a binomial proportion. Statistical Science, 16(2), 101–133.

[6] Caudle, A. S., Yang, W. T., Krishnamurthy, S., et al. (2016). Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection. Journal of Clinical Oncology, 34(10), 1072–1078.

[7] Caudle, A. S., Yang, W. T., Mittendorf, E. A., et al. (2015). Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: A prospective feasibility trial. JAMA Surgery, 150(2), 137–143.

[8] Cohen, B. L., Collier, A. L., Kelly, K. N., et al. (2020). Surgical management of the axilla in patients with occult breast cancer (cT0 N+) after neoadjuvant chemotherapy. Annals of Surgical Oncology, 27(6), 1830–1841.

[9] Donker, M., Straver, M. E., Wesseling, J., et al. (2015). Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: The MARI procedure. Annals of Surgery, 261(2), 378–382.

[10] Hessler, L. K., Molitoris, J. K., Rosenblatt, P. Y., et al. (2017). Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: Analysis of the National Cancer Database. Annals of Surgical Oncology, 24(10), 2907–2914.

[11] Holt, A. C., Haji, F., McCloskey, S., & Baker, J. L. (2023). De-escalation of surgery for occult breast cancer with axillary metastasis. Surgery, 174(2), 410–412.

[12] Houssami, N., Macaskill, P., von Mankowitz, G., Marinovich, M. L., & Mamounas, E. (2012). Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. European Journal of Cancer, 48(18), 3342–3354.

[13] Huang, K. Y., Zhang, J., Fu, W. F., Lin, Y. X., & Song, C. G. (2020). Different clinicopathological characteristics and prognostic factors for occult and non-occult breast cancer: Analysis of the SEER database. Frontiers in Oncology, 10, 1420.

[14] Johnson, H. M., Irish, W., Vohra, N. A., & Wong, J. H. (2019). The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): A population analysis. Breast Cancer Research and Treatment, 177(1), 155–164.

[15] Kuehn, T., Bauerfeind, I., Fehm, T., et al. (2013). Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study. The Lancet Oncology, 14(7), 609–618.

[16] Kuemmel, S., Heil, J., Rueland, A., et al. (2022). A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Annals of Surgery, 276(5), e553–e562.

[17] Loi, F., Rassy, E., Grinda, T., et al. (2025). Targeted axillary dissection in breast cancer: Current evidence and ongoing trials. European Journal of Surgical Oncology, 52(3), 111377.

[18] Loibl, S., André, F., Bachelot, T., et al. (2024). Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 35(2), 159–182.

[19] Mamtani, A., Barrio, A. V., King, T. A., et al. (2016). How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Annals of Surgical Oncology, 23(11), 3467–3474.

[20] Montagna, G., Mrdutt, M. M., Sun, S. X., et al. (2024). Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncology, 10(6), 793–798.

[21] Muslumanoglu, M., Cabioglu, N., Igci, A., et al. (2025). Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided. Cancer, 131(1), e35610.

[22] National Comprehensive Cancer Network. (2025). Breast cancer (Version 5.2025).

[23] Ofri, A., & Moore, K. (2020). Occult breast cancer: Where are we at? The Breast, 54, 211–215.

[24] Pilewskie, M., & Morrow, M. (2017). Axillary nodal management following neoadjuvant chemotherapy: A review. JAMA Oncology, 3(4), 549.

[25] Samiei, S., Simons, J. M., Engelen, S. M. E., et al. (2021). Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: A systematic review and meta-analysis. JAMA Surgery, 156(6), e210891.

[26] Straver, M. E., Loo, C. E., Alderliesten, T., Rutgers, E. J. T., & Vranken Peeters, M. T. F. D. (2010). Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. British Journal of Surgery, 97(8), 1226–1231.

[27] Symmans, W. F., Peintinger, F., Hatzis, C., et al. (2007). Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. Journal of Clinical Oncology, 25(28), 4414–4422.

[28] Symmans, W. F., Yau, C., Chen, Y. Y., et al. (2021). Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: An analysis of data from the I-SPY2 randomized clinical trial. JAMA Oncology, 7(11), 1654–1663.

[29] Walker, G. V., Smith, G. L., Perkins, G. H., et al. (2010). Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer, 116(17), 4000–4006.